Art. 7 Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…

Community marketing authorisation

In forcesince 7 Aug 2009cited 11×
1.

The person responsible for placing on the market an orphan medicinal product may request that authorisation to place the medicinal product on the market be granted by the Community in accordance with the provisions of Regulation (EEC) No 2309/93 without having to justify that the medicinal product qualifies under Part B of the Annex to that Regulation.

2.

A special contribution from the Community, distinct from that provided for in Article 57 of Regulation (EEC) No 2309/93, shall be allocated every year to the Agency. The contribution shall be used exclusively by the Agency to waive, in part or in total, all the fees payable under Community rules adopted pursuant to Regulation (EEC) No 2309/93. A detailed report of the use made of this special contribution shall be presented by the Executive Director of the Agency at the end of each year. Any surplus occurring in a given year shall be carried forward and deducted from the special contribution for the following year.

3.

The marketing authorisation granted for an orphan medicinal product shall cover only those therapeutic indications which fulfil the criteria set out in Article 3. This is without prejudice to the possibility of applying for a separate marketing authorisation for other indications outside the scope of this Regulation.

The 10 that are cited most themselves, of 11.

  • Judgment of the General Court (Sixth Chamber), 22 January 2015. Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines AgencDecision

    As regards the marketing authorisation of designated orphan medicinal products, Article 7 of Regulation No 141/2000 lays down the procedure to be followed and Article 8 thereof sets out the conditions attaching to the market exclusivity …

    22 Jan 2015 · 62012TJ0140

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. CSL Behring GmbH v European Commission and European Medicines Agency (EMADecision

    Thirdly, should a competing undertaking obtain designation as an orphan medicinal product for a medicinal product similar to human fibrinogen, but having a significant benefit, it still has to obtain marketing authorisation for that …

    9 Sep 2010 · 62007TJ0264

  • Judgment of the General Court (Second Chamber) of 5 December 2018. Bristol-Myers Squibb Pharma EEIG v European Commission and European MedicDecision

    Similarly, with regard to the argument put forward by the applicant in the alternative that Empliciti (Elotuzumab) should not have been compared with the authorised medicinal product Kyprolis (Carfilzomib) after 3 July 2015, that is, after …

    5 Dec 2018 · 62016TJ0329

  • Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision

    In addition, it must be emphasised that Article 7(3) of Regulation No 141/2000 allows, specifically when an MA is granted for an orphan medicinal product, account to be taken of cases of partial overlap with MAs for other medicinal …

    23 Sep 2020 · 62019TJ0549

  • Judgment of the General Court (Seventh Chamber) of 16 May 2019 (Extracts). GMP-Orphan (GMPO) v European Commission.Decision

    16 May 2019 · 62017TJ0733

  • Order of the President of the General Court of 23 November 2018. GMP-Orphan (GMPO) v European Commission.Decision

    It is apparent from the provisions of Regulation No 141/2000, and specifically from Article 5(1) and Article 7(3) thereof, that the procedure for the designation of a product as an orphan medicinal product has two separate stages, the …

    23 Nov 2018 · 62017TO0733

  • Opinion of Advocate General Emiliou delivered on 11 July 2024. Mylan IRE Healthcare Ltd v European Commission.Decision

    … Вж. също Известие на Комисията относно прилагането на членове 3, 5 и 7 от Регламент (ЕО) № 141/2000 за лекарствата сираци (ОВ C 424, 2016 г., стр. …

    11 Jul 2024 · 62022CC0237

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision

    It is apparent from a reading of Article 5(12)(b) of Regulation No 141/2000 in conjunction with Article 7(3) of the regulation that at the time of the MA the COMP is to carry out a complete re-evaluation of the designation criteria in a …

    24 Sep 2025 · 62022TJ0483

  • Act (EU) 2026/72Law

    … е предназначен за покриване на специалните вноски, предвидени в член 7 от Регламент (ЕО) № 141/2000, различни от тези, предвидени в член …

  • Judgment of the Court (Eighth Chamber) of 4 October 2024. Mylan IRE Healthcare Ltd v European Commission.Decision

    Освен това в своето Известие относно прилагането на членове 3, 5 и 7 от Регламент № 141/2000 за лекарствата сираци Комисията уточнява, …

    4 Oct 2024 · 62022CJ0237